#United States #Irvine #EnChannel Medical #Acutus Medical #AcQMap

EnChannel Medical Expands Capabilities with AcQMap Acquisition

On July 1, 2025, EnChannel Medical Ltd., a leading name in cardiac electrophysiology, made headlines by signing a definitive agreement to acquire assets related to the AcQMap™ High Resolution Imaging and Mapping platform from Acutus Medical Inc. This acquisition not only includes significant intellectual property and quality regulatory documentation, but also a limited number of AcQMap™ systems and associated catheter devices intended for research and development.

A key takeaway from this acquisition is that it substantially enhances EnChannel's intellectual property portfolio, incorporating advanced innovations in non-contact mapping (NCM) technologies. These technologies are central to effective atrial fibrillation (AF) mapping, which is vital for delivering personalized treatment solutions. EnChannel Medical’s CEO, Jun Feng, expressed the importance of this strategic move, stating, "This strategic acquisition accelerates our mission to visualize and treat AF with unprecedented efficiency and precision."

Revolutionizing Electrophysiological Mapping

Electrophysiological mapping traditionally relies on contact mapping systems, which gather electrical signals by making physical contact with various small areas of heart tissue. While this method produces useful data, it is quite time-intensive and fails to capture the intricate dynamics of irregular activation patterns such as those found in AF. This often results in an average of crucial details, leading to reduced mapping accuracy.

In contrast, non-contact mapping (NCM) reconstructs the chamber's electrical activity using multiple electrodes placed throughout the atrial chamber cavity. This technique allows for a holistic, single-beat visualization of activation across the atrial chamber at any given moment, drastically improving mapping efficiency and preserving the complexity of both standard and irregular heart rhythms.

The AcQMap™ Technology

The AcQMap™ platform represents a second-generation NCM technology, progressing beyond the earlier voltage-to-voltage mapping modes established by Endocardial Solutions, now a part of Abbott. It delivers enhanced spatial resolution and accuracy through voltage-to-charge-density mapping, making it a significant advancement in the field of cardiac mapping.

Third-Generation Advancements

EnChannel Medical is also pioneering its proprietary Action Potential Mapping, regarded as a third-generation advancement in NCM technology. This approach successfully reconstructs both the depolarization and repolarization dynamics, addressing a gap left by conventional mapping solutions. The ability to monitor repolarization could lead to a deeper understanding of AF's underlying mechanisms, thus enabling tailored treatment approaches for persistent AF patients.

Graydon Beatty, the Chief Scientific Officer of EnChannel Medical, elaborated on the implications of this acquisition. He noted that the company played a pivotal role in advancing all three generations of NCM. Beatty highlighted how each evolution has built upon its predecessor, contributing to the development of methods that enhance the accuracy and effectiveness of electrophysiological treatments.

A Comprehensive Electrophysiology Ecosystem

This acquisition unifies the company's legacy methods and resources, positioning EnChannel Medical to establish a comprehensive electrophysiology ecosystem. This ecosystem aims to decode the mechanisms behind AF, optimize personalized treatment options, and ultimately enhance clinical outcomes for patients suffering from this condition.

Founded in 2020, EnChannel Medical is a collaboration of seasoned electrophysiology professionals from the United States and China. The firm seeks to develop a holistic platform that integrates magnetic-impedance navigation, intracardiac echocardiography, full-chamber 5D action-potential mapping, and pulsed-field ablation. Their goal? To provide safe, individualized treatment for AF patients and redefine care in this critical area of cardiology.

For further information, visit EnChannel Medical's official website and connect with them on LinkedIn. Note that EnChannel's mapping and ablation technologies are investigational devices, limited to research use under federal law.